Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial.
- DOI
- 10.1038/s41416-025-02983-w
- Published
- 2025 Jun
- Container
- British journal of cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41416-025-02983-w,
title = {Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial.},
author = {Yip D and Zalcberg J and Blay JY and Eriksson M and Espinoza D and Price T and Marreaud S and Italiano A and Steeghs N and Boye K and Underhill C and Gebski V and Simes J and Gelderblom H and Joensuu H},
year = {2025},
journal = {British journal of cancer},
doi = {10.1038/s41416-025-02983-w},
url = {https://doi.org/10.1038/s41416-025-02983-w}
}RIS
TY - JOUR TI - Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial. AU - Yip D AU - Zalcberg J AU - Blay JY AU - Eriksson M AU - Espinoza D AU - Price T AU - Marreaud S AU - Italiano A AU - Steeghs N AU - Boye K AU - Underhill C AU - Gebski V AU - Simes J AU - Gelderblom H AU - Joensuu H PY - 2025 JO - British journal of cancer DO - 10.1038/s41416-025-02983-w UR - https://doi.org/10.1038/s41416-025-02983-w ER -
APA
D, Y., J, Z., JY, B., M, E., D, E., T, P., S, M., A, I., N, S., K, B., C, U., V, G., J, S., H, G., & H, J. (2025). Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial.. British journal of cancer. https://doi.org/10.1038/s41416-025-02983-w
Source records
- pubmed · retrieved 2026-09-26T05:16:05.560Z